Shares of Grail, Inc. (NASDAQ:GRAL - Get Free Report) fell 7.4% on Tuesday . The company traded as low as $18.14 and last traded at $18.21. 127,209 shares were traded during mid-day trading, a decline of 67% from the average session volume of 383,007 shares. The stock had previously closed at $19.67.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on GRAL shares. Wolfe Research initiated coverage on shares of Grail in a report on Friday, November 15th. They set a "peer perform" rating for the company. Guggenheim began coverage on shares of Grail in a report on Thursday, October 17th. They issued a "neutral" rating for the company. Finally, Morgan Stanley began coverage on Grail in a report on Wednesday, November 27th. They set an "equal weight" rating and a $16.00 target price on the stock.
Get Our Latest Report on GRAL
Grail Trading Down 9.2 %
The firm's 50-day moving average price is $17.62.
Insider Activity
In related news, major shareholder Chun R. Ding acquired 16,200 shares of the stock in a transaction that occurred on Wednesday, October 9th. The stock was purchased at an average price of $12.92 per share, with a total value of $209,304.00. Following the transaction, the insider now owns 3,644,855 shares of the company's stock, valued at approximately $47,091,526.60. This trade represents a 0.45 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Robert P. Ragusa sold 123,454 shares of the business's stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $14.02, for a total value of $1,730,825.08. Following the completion of the sale, the chief executive officer now directly owns 612,661 shares in the company, valued at approximately $8,589,507.22. The trade was a 16.77 % decrease in their position. The disclosure for this sale can be found here.
Grail Company Profile
(
Get Free Report)
GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.
See Also
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
